Chemical Synthesis Of A Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF) CDNA And Its Expression Analysis | 17239
ISSN: 2155-952X

Journal of Biotechnology & Biomaterials
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Chemical synthesis of a recombinant human granulocyte colony stimulating factor (rhG-CSF) cDNA and its expression analysis

5th World Congress on Biotechnology

Salman A H Alrokayan

Posters: J Biotechnol Biomater

DOI: 10.4172/2155-952X.S1.028

Recently, granulocyte colony-stimulating factor (G-CSF) has been recognized as an important molecule for the treatment of a wide range of complex ailments such as cancer, AIDS, H1N1 influenza, cardiac and neurological diseases. Such a vast therapeutic potential of G-CSF has lured the scientists to utilize biotechnological approaches for the synthesis of this pharmacologically active agent. This study describes the use of a synthetic G-CSF cDNA molecule and its efficient utilization of producing the target protein by a simple cloning protocol. It was constructed the entire synthetic cDNA using a DNA synthesizer with the aim to increase its expression level by specific sequence modifications at the 5? end of the G-CSF coding region and decreasing the GC content without altering the predicted amino acids sequence. The identity of the resulting protein was confirmed by the highly specific enzyme-linked immunosorbent assay. In conclusion, a synthetic G-CSF cDNA in combination with the recombinant DNA protocol offers a rapid and reliable strategy for synthesizing the target protein. However, the commercial utilization of this methodology requires rigorous validation and quality control.
Salman A H Alrokayan has completed his PhD from Nottingham University, United Kingdom. He is the director of bionanotechnologyProgram, Visiting professor (Leeds University UK). He has 5 patents and published more than 50 papersin reputed journals and has been serving as an editorial board of ?Journal of Biomaterials and Tissue engineering? as a Regional Editor ? USA.